177Lu-PSMA-617 for metastatic prostate cancer in India

Lancet Reg Health Southeast Asia. 2024 Sep 12:30:100484. doi: 10.1016/j.lansea.2024.100484. eCollection 2024 Nov.

Aruni Ghose^{1

2

3

4

5

6}, Soirindhri Banerjee⁷, Partha S Choudhury⁸, Akash Maniam^{9

10}, Manoj Gupta⁸, Giuseppe L Banna^{9

11}, Nikhil Vasdev^{4

12

13}, Amit Ghose¹⁴, Vanita Noronha¹⁵, Swarupa Mitra¹⁶

¹ United Kingdom and Ireland Global Cancer Network, UK.
² Barts Cancer Centre, St. Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
³ Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London, UK.
⁴ Hertfordshire and Bedfordshire Urological Cancer Centre, Lister Hospital, East and North Hertfordshire NHS Trust, Stevenage, UK.
⁵ Department of Oncology, Medway NHS Foundation Trust, Gillingham, UK.
⁶ Inequalities Network, European Cancer Organisation, Brussels, Belgium.
⁷ Department of Radiation Oncology, IPGMER and SSKM Hospital, Kolkata, India.
⁸ Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India.
⁹ Department of Medical Oncology, Portsmouth Hospitals University NHS Trust, Portsmouth, UK.
¹⁰ Caribbean Cancer Research Institute, Trinidad and Tobago.
¹¹ Faculty of Science and Health, School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, UK.
¹² School of Life and Medical Sciences, University of Hertfordshire, Hatfield, UK.
¹³ Apollo Hospitals Educational and Research Foundation, India.
¹⁴ Department of Urology, Apollo Multispeciality Hospitals, Kolkata, India.
¹⁵ Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, India.
¹⁶ Fortis Cancer Institute, Fortis Memorial Research Institute, Gurugram, India.

No abstract available